Baudax Bio rises on positive interim data from trial

Baudax Bio

27/03/2023 14:07

** Shares of drug developer Baudax Bio Inc  BXRX.O  rise
~13% to $1.75 premarket 
    ** Company cites interim data from mid-stage study, says its
experimental drug to relax muscles during surgical procedures
showed "good or excellent" intubating conditions  
    ** The drug candidate, BX1000, is used as a neuromuscular
blockade (NMB), which helps doctors intubate, or insert a
breathing tube in patients, during surgery     
    ** Company says BX1000, combined with its reversal agent
BX3000, could help patients emerge more quickly from anesthesia
    ** BXRX expects top line results from the study in late
April or early May 
    ** Up to Friday's close, stock had tumbled ~98% in past 12
months

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))